Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
GANTANOL vs CETAMIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydropteroate synthase, preventing folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate production. The combination produces sequential blockade of folate metabolism, leading to bactericidal activity.
CETAMIDE is an antimicrobial combination of sulfadiazine (a sulfonamide) and trimethoprim. Sulfonamides inhibit dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism.
Urinary tract infections,Acute otitis media,Acute exacerbations of chronic bronchitis,Traveler's diarrhea,Pneumocystis jirovecii pneumonia (treatment and prophylaxis),Toxoplasmosis (prophylaxis in immunocompromised patients),Shigellosis,Nocardiosis
Urinary tract infections,Acute otitis media,Shigellosis,Pneumocystis jirovecii pneumonia,Traveler's diarrhea (off-label)
800 mg orally every 12 hours for 5-7 days.
500 mg orally every 6 hours; maximum 4 g per day.
Terminal elimination half-life: 8-12 hours in healthy adults; prolonged in renal impairment (up to 24-36 hours in Cr Cl <30 m L/min).
6-8 hours; prolonged (up to 30 hours) in severe renal impairment (Cr Cl <30 m L/min).
Sulfamethoxazole is metabolized primarily by N-acetylation and glucuronidation. Trimethoprim undergoes O-demethylation and oxidative metabolism. Both are excreted renally.
Sulfadiazine is metabolized via acetylation (N-acetyltransferase) and glucuronidation; trimethoprim is metabolized by oxidative pathways (N-oxidation, N-demethylation) and conjugated with glucuronic acid.
Renal: 70% as unchanged drug; hepatic metabolism: 20% (glucuronidation); fecal: 10%.
Primarily renal (85-90%) as unchanged drug; biliary/fecal (5-10%).
85-90% primarily to albumin.
20-25% bound to albumin.
0.15-0.3 L/kg; indicates limited extravascular distribution, primarily confined to plasma and interstitial fluid.
0.5-0.8 L/kg; indicates distribution into total body water.
Oral: 90-95%; Intravenous: 100%.
Oral: 90-100% (well absorbed).
Cr Cl 30-60 m L/min: 800 mg every 24 hours. Cr Cl 15-29 m L/min: 800 mg every 48 hours. Cr Cl <15 m L/min or hemodialysis: 800 mg every 48-72 hours.
Cr Cl 10-50 m L/min: 250 mg every 6 hours. Cr Cl <10 m L/min: 250 mg every 12 hours.
Child-Pugh Class A: no adjustment. Child-Pugh Class B: reduce dose by 50%. Child-Pugh Class C: use contraindicated.
Child-Pugh Class C: avoid use; Class A or B: no adjustment needed.
15 mg/kg orally every 6 hours for children 2 months to 12 years; maximum 2 g/day.
10-15 mg/kg orally every 6 hours; maximum 100 mg/kg/day.
Use with caution; start at 400 mg every 12 hours due to age-related renal decline. Monitor for toxicity.
Consider dose reduction based on renal function; initial dose not to exceed 2 g per day.
Fatal hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and hepatic necrosis have occurred. Also associated with fatal hematologic toxicities (e.g., agranulocytosis, aplastic anemia). Coadministration with methotrexate increases risk of megaloblastic anemia.
Sulfonamides have been associated with fatal reactions such as Stevens-Johnson syndrome, toxic epidermal necrolysis, agranulocytosis, aplastic anemia, and other blood dyscrasias.
Hypersensitivity and skin reactions (discontinue at first sign of rash). Hemolysis in G6PD-deficient patients. Risk of hepatotoxicity, including cholestatic jaundice and hepatic necrosis. Photosensitivity. Severe renal and hepatic impairment. Use caution in elderly, folate-deficient patients, and those with megaloblastic anemia. Possible hyperkalemia with high-dose treatment in renal impairment.
Increased risk of hypersensitivity reactions (SJS, TEN); hematologic toxicity (agranulocytosis, thrombocytopenia); hepatotoxicity; renal toxicity due to crystalluria; hemolytic anemia in G6PD-deficient patients; photosensitivity.
Hypersensitivity to sulfonamides, trimethoprim, or any component. History of drug-induced hypersensitivity reactions. Severe hepatic impairment. Severe renal impairment (Cr Cl <15 m L/min) not on dialysis. Megaloblastic anemia due to folate deficiency. Pregnancy (especially first trimester) and lactation (near term). Concurrent use with dofetilide.
Hypersensitivity to sulfonamides or trimethoprim; severe hepatic or renal impairment; megaloblastic anemia due to folate deficiency; pregnancy (especially first trimester and near term); lactation; pediatric patients <2 months of age.
Avoid alcohol during and for 3 days after therapy. Limit high-potassium foods if using high doses. Take with food to reduce GI upset.
No significant food interactions known. No dietary restrictions required.
First trimester: Sulfonamides cross the placenta; risk of kernicterus in neonates if used near term. Animal studies show cleft palate and other anomalies at high doses. Human data insufficient; avoid use in first trimester unless benefit outweighs risk. Second/third trimester: Risk of neonatal jaundice and hemolytic anemia in G6PD deficiency; contraindicated after 38 weeks or near delivery due to kernicterus risk.
Pregnancy category C. First trimester: Potential risk of neural tube defects based on animal studies. Second and third trimesters: Increased risk of premature closure of ductus arteriosus and oligohydramnios due to prostaglandin synthesis inhibition. Limited human data; avoid unless benefit outweighs risk.
Sulfamethoxazole is excreted into breast milk with a milk-to-plasma ratio of approximately 0.1. Based on limited data, not recommended in nursing mothers at term due to potential for neonatal kernicterus and hemolysis in G6PD-deficient infants; caution if used in preterm or jaundiced infants.
Excreted in breast milk in low quantities. M/P ratio not established. Potential risk of adverse effects in nursing infants (e.g., renal dysfunction, bleeding). Use with caution if alternative therapies are not available.
No specific dose adjustments required for pregnancy alone. Consider increased clearance in pregnancy; monitor for therapeutic efficacy. Use lowest effective dose for shortest duration.
No standard dosing adjustment during pregnancy. Increased renal clearance and volume of distribution in pregnancy may reduce efficacy; consider dose titration based on clinical response. Avoid in third trimester if possible.
Gantanol (sulfamethoxazole) is a sulfonamide antibiotic often used in combination with trimethoprim (co-trimoxazole). Monitor for hypersensitivity reactions, especially in HIV patients. Adjust dose in renal impairment (Cr Cl <30 m L/min avoid). Hydrate to prevent crystalluria.
Cetamide (sulfacetamide sodium) is a topical ophthalmic sulfonamide used for bacterial conjunctivitis. Monitor for hypersensitivity, as cross-allergy with other sulfonamides may occur. Use with caution in patients with dry eye syndrome or corneal abrasions. Avoid prolonged use to prevent superinfection. Administer with clean hands and do not touch dropper tip to any surface.
Take with a full glass of water to prevent kidney stones.,Complete full course even if feeling better.,Avoid prolonged sun exposure; use sunscreen.,Report rash, fever, or sore throat immediately.,Do not use if allergic to sulfa drugs.
Wash hands before and after applying the eye drops.,Do not touch the dropper tip to your eye or any other surface.,Wait 5 minutes between different eye drops if using more than one type.,Complete the full course of treatment even if symptoms improve.,Do not wear contact lenses during treatment unless directed by your doctor.,Stop use and contact your doctor if you experience rash, itching, or swelling.,Keep the bottle tightly closed when not in use and store at room temperature.
No interactions on record
"Sulfacetamide may reduce the efficacy of picosulfuric acid, a stimulant laxative, through antibiotic-mediated disruption of the gut microbiota. The conversion of picosulfate to its active metabolite, BHPM, relies on bacterial azoreductase enzymes in the colon. Sulfacetamide's antibacterial activity against colonic flora can decrease this bioactivation, leading to diminished laxative effect and potential treatment failure for constipation or bowel preparation."
"The risk or severity of adverse effects can be increased when Methenamine is combined with Sulfacetamide."
"The risk or severity of adverse effects can be increased when Sulfacetamide is combined with Mecamylamine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about GANTANOL vs CETAMIDE, answered by our medical review team.
GANTANOL is a Sulfonamide Antibiotic that works by Sulfamethoxazole is a sulfonamide that inhibits bacterial dihydropteroate synthase, preventing folate synthesis. Trimethoprim inhibits bacterial dihydrofolate reductase, blocking tetrahydrofolate production. The combination produces sequential blockade of folate metabolism, leading to bactericidal activity.. CETAMIDE is a Sulfonamide antibiotic that works by CETAMIDE is an antimicrobial combination of sulfadiazine (a sulfonamide) and trimethoprim. Sulfonamides inhibit dihydropteroate synthase, blocking folate synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between GANTANOL and CETAMIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of GANTANOL is: 800 mg orally every 12 hours for 5-7 days.. The standard adult dose of CETAMIDE is: 500 mg orally every 6 hours; maximum 4 g per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between GANTANOL and CETAMIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. GANTANOL is classified as Category C. First trimester: Sulfonamides cross the placenta; risk of kernicterus in neonates if used near term. Animal studies show cleft palate and other anomalies at high doses. Human data . CETAMIDE is classified as Category C. Pregnancy category C. First trimester: Potential risk of neural tube defects based on animal studies. Second and third trimesters: Increased risk of premature closure of ductus art. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.